M John Chapman
Overview
Explore the profile of M John Chapman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
230
Citations
18636
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Corsini A, Ginsberg H, Chapman M
Pharmacol Ther
. 2025 Feb;
268:108812.
PMID: 39947256
As a major regulator of LDL receptor (LDLR) activity and thus of LDL-cholesterol (LDL-C) levels, proprotein convertase subtilisin/kexin type 9 (PCSK9) represents an obvious therapeutic target for lipid lowering. The...
2.
Packard C, Boren J, Chapman M
J Am Coll Cardiol
. 2025 Jan;
85(4):e53-e54.
PMID: 39880548
No abstract available.
3.
Toth P, Chapman M, Parhofer K, Nelson J
Am Heart J Plus
. 2024 Apr;
17:100148.
PMID: 38559888
None of the clinical trials of omega-3 fatty acids using combinations of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) were able to show any effect on cardiovascular outcomes, despite reductions...
4.
Bjornson E, Adiels M, Taskinen M, Burgess S, Chapman M, Packard C, et al.
J Am Coll Cardiol
. 2024 Jan;
83(3):385-395.
PMID: 38233012
Background: Lipoprotein(a) (Lp(a)) is recognized as a causal factor for coronary heart disease (CHD) but its atherogenicity relative to that of low-density lipoprotein (LDL) on a per-particle basis is indeterminate....
5.
Ponnaiah M, Zakiev E, Lhomme M, Rached F, Camont L, Serrano Jr C, et al.
Atheroscler Plus
. 2024 Jan;
55:21-30.
PMID: 38226021
Aim: High-density lipoprotein (HDL) particles in ST-segment elevation myocardial infarction (STEMI) are deficient in their anti-atherogenic function. Molecular determinants of such deficiency remain obscure. Methods: Five major HDL subpopulations were...
6.
Chapman M, Orsoni A, Mellett N, Nguyen A, Robillard P, Shaw J, et al.
J Lipid Res
. 2023 Dec;
65(2):100494.
PMID: 38160756
HDL particles vary in lipidome and proteome, which dictate their individual physicochemical properties, metabolism, and biological activities. HDL dysmetabolism in nondiabetic hypertriglyceridemia (HTG) involves subnormal HDL-cholesterol and apoAI levels. Metabolic...
7.
Chapman M, Packard C
J Am Coll Cardiol
. 2023 Apr;
81(16):1565-1568.
PMID: 37076210
No abstract available.
8.
Chapman M, Mason R
Pharmacol Ther
. 2022 Jun;
240:108237.
PMID: 35772589
Atherosclerotic plaques associated with acute coronary syndromes (ACS), i.e. culprit lesions, frequently feature a ruptured fibrous cap with thrombotic complications. On imaging, these plaques exhibit a low attenuation, lipid-rich, necrotic...
9.
Therond P, Chapman M
Curr Opin Lipidol
. 2022 Jun;
33(3):199-207.
PMID: 35695616
Purpose Of Review: To better define the metabolism of sphingosine-1-phosphate (S1P), its transport in plasma and its interactions with S1P receptors on vascular cells, and to evaluate the effect of...
10.
Chapman M, Zamorano J, Parhofer K
Pharmacol Ther
. 2022 Mar;
237:108172.
PMID: 35304222
Atherosclerotic cardiovascular disease (ASCVD) and its atherothrombotic complications impose a substantial disease burden in Europe, representing a cost of €210 billion per year for the European Union. Hypertriglyceridemia, a major...